Jastreboff, Yale School of Medicine, New Haven, CT, and colleagues present three-year safety outcomes for tirzepatide, along with its effectiveness in reducing weight and preventing the progression to type 2 diabetes in individuals with both obesity and prediabetes
Its low molecular weight (~340 Da) means it reaches tissue compartments that larger peptides may not, and its stability profile is well-suited to combination formulations
Free radicals are unstable molecules that can cause damage to your cells
Longer-term L-citrulline supplementation improves vascular function: A meta-analysis of randomized trials
6.6 Effects on renal functions The result of clinical trials of tirzepatide on kidney function indicates potential renal advantages, especially in individuals with type-2 diabetes (T2D) and a heightened cardiovascular risk.In the SURPASS-4 (NCT03730662) trial, tirzepatide was observed to reduce occurrence of the composite kidney endpoint (like eGFR decline of at least 40% from baseline, end-stage kidney disease, death due to kidney failure, or new-onset macro albuminuria) in comparison to those receiving insulin glargine
However, tirzepatide is a dual GIP/GLP-1 agonist with a slightly more complex structure, including its unique glucose-dependent insulinotropic polypeptide receptor activity
